Efficacy evaluation and preliminary mechanism study of acupuncture combined with auricular embedding pills in the treatment of peripheral neuropathy after breast cancer paclitaxel chemotherapy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076726

Enrollment

Unknown

Registered

2023-10-17

Start date

2023-07-27

Completion date

Unknown

Last updated

2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Nursing group:Usual Nursing Care

Acupuncture Group:Usual Nursing Care+ Acupuncture

Acupuncture Combined with Auricular Pressing Group:Usual Nursing Care+ Acupuncture+ Auricular Pressure

Eligibility

Sex/Gender

Female

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) aged 18 or above; (2) Karnofsky score =70; (3) Plan to receive 3-4 cycles of 80mg/m neoadjuvant/adjuvant paclitaxel liposome chemotherapy; (3) Sign informed consent.

Exclusion criteria

Exclusion criteria: (1) known metastatic breast cancer; (2) The presence of peripheral neuropathy within 28 days after the screening consent; (3) Current use of antineuropathic pain drugs, such as gabapentin, pregabalin, or duloxetine.

Design outcomes

Primary

Measure	Time frame
National Cancer Institute-Common Terminology Criteria for Adverse Events,NCI-CTCAE;	—

Secondary

Measure	Time frame
Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-Neurotoxicity,FACT/GOG-Ntx;Blood Serum NGF and BDNF;	—

Countries

China

Contacts

Public ContactLu Jing

The First Affiliated Hospital of Nanjing Medical University

lujing0728@163.com+86 150 6221 6761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026